Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 5/24/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.48 | 0.34 | 38.91 |
| EPS, GAAP | 0.45 | 0.34 | 0.34 |
| Consensus Estimate | 0.41 | 0.29 | 42.04 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 1.74 | 1.56 | 11.28 |
| EPS, GAAP | 0.52 | 1.51 | -65.14 |
| Consensus Estimate | 0.75 | 1.61 | -53.21 |
| CBST | Industry Average | |
| P/E (TTM) | 74.02 | NA |
| P/E (Forward) | 23.99 | NA |
| PEG Ratio | 1.52 | 2.17 |
| Price/Sales | 3.14 | 4.18 |
| Beta | 0.70 | 0.62 |
| 4/19/2012 | Stocks To Watch: Bank of America, EBay, Morgan Stanley (WSJ.com) |
| 4/18/2012 | Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT) (24/7 Wall St) |
| 3/30/2012 | These two metrics can tell you a lot. (The Motley Fool) |
| 3/23/2012 | Top Analyst Upgrades & Downgrades (AET, MO, CVH, CBST, DFS, EXM, HFC, MWW, RAI, XLNX, ZNGA) (24/7 Wall St) |
| 3/12/2012 | Tranzyme's ulimorelin fails as placebo performs better than expected. (The Motley Fool) |
![[sm061210things]](http://s.wsj.net/public/resources/images/PF-AC562_sm0612_C_20120514113337.jpg)
![[sm0612wedding4]](http://s.wsj.net/public/resources/images/PF-AC579_sm0612_C_20120515172853.jpg)
![[sm0612strat]](http://s.wsj.net/public/resources/images/PF-AC580_sm0612_C_20120515180019.jpg)
![[sm0612roi]](http://s.wsj.net/public/resources/images/PF-AC573_sm0612_C_20120515125902.jpg)
